Legend Biotech Corp
LEGNHealthcare|Biotechnology|USA
$27.08
-0.32 (-1.17%)
Tangible Book
$5.02
Clinical Trials (45)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05539430 Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma | Gastric Cancer, Gastroesophageal-junction Cancer | P1 | Active | 56 | Open-label | LB1908 |
| NCT05680922 DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung | P1 | Active | 41 | Open-label | LB2102 |
| NCT06313957 A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | P1 | Recruiting | 42 | Open-label | LUCAR-20SP cells |
| NCT07331272 A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) | Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM) | P1 | Recruiting | 38 | Open-label | LUCAR-G79D T cells |
| NCT06494371 A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma | P1 | Recruiting | 32 | Open-label | LCAR-HL30 cells |
| NCT07002112 The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies | Relapsed/Refractory B-cell Malignancies | P1 | Recruiting | 30 | Open-label | CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product |
| NCT06395870 Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | P1 | Recruiting | 33 | Open-label | LUCAR-G39D cells product |
| NCT07294625 A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | Early P1 | Recruiting | 36 | Open-label | LVIVO-TaVec200 product |
| NCT06653556 A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Early P1 | Recruiting | 34 | Open-label | LCAR-AIO T cells |
| NCT07100067 LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma(MM) | N/A | Recruiting | 35 | Open-label | LCAR- F33S cells intravenous infusion |
| NCT07095075 A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases | Relapsed/Refractory Autoimmune Diseases | Early P1 | Recruiting | 36 | Open-label | LUCAR-DKS1 NK cells |
| NCT03090659 LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | Refractory or Relapsed Multiple Myeloma | P1P2 | Unknown | 100 | Open-label | LCAR-B38M CAR-T cell injection |
| NCT03758417 A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Terminated | 123 | Open-label | LCAR-B38M CAR-T Cell |
| NCT05292898 A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia | Acute Lymphocytic Leukemia | P1 | Terminated | 10 | Open-label | LCAR-AIO Cells |
| NCT04973527 LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor | T Cell Lymphoma, T-cell Leukemia | P1 | Terminated | 9 | Open-label | Efficacy of LCAR-T2C CAR-T cells |
| NCT07049081 A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases | Relapsed/Refractory Autoimmune Diseases | P1 | Terminated | 3 | Open-label | LUCAR-G79 T cells |
| NCT04601935 A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Unknown | 34 | Open-label | LCAR-BCX cells product |
| NCT04467853 A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors | Solid Tumors, Adult | P1 | Terminated | 34 | Open-label | LCAR-C18S cells |
| NCT06197178 A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) | Advanced Gastrointestinal Tumors | P1 | Terminated | 17 | Open-label | LCAR-G08 cells |
| NCT04176913 Study of LUCAR-20S in Patients With R/R NHL | Diffuse Large B Cell Lymphoma, Follicular Lymphoma | P1 | Terminated | 7 | Open-label | LUCAR-20S CAR-T cells |
| NCT03672253 CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | Multiple Myeloma, Multiple Myeloma in Relapse | P1 | Unknown | 20 | Open-label | CAR-T Re-treatment |
| NCT05498545 Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Terminated | 8 | Open-label | LUCAR-B68 cells product |
| NCT05654779 CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Terminated | 4 | Open-label | LCAR-AMDR Cells Product |
| NCT04219319 LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma | CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia) | P1 | Terminated | 4 | Open-label | Efficacy of LCAR-T2C CAR-T cells |
| NCT06295549 Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | P1 | Terminated | 11 | Open-label | LUCAR-G39P cells product |
| NCT04562298 A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer | Epithelial Ovarian Cancer | P1 | Terminated | 15 | Open-label | LCAR-M23 cells |
| NCT05318963 Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma | B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | P1 | Terminated | 14 | Open-label | LCAR-AIO cells product |
| NCT04712864 Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory | P1 | Unknown | 50 | Open-label | LB1901 |
| NCT03593109 A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma | Lymphoma, B-Cell | P1 | Terminated | 1 | Open-label | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy |
| NCT06869278 A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases | Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD) | P1 | Withdrawn | — | Open-label | LCAR-AIO T cells |
| NCT07628582 A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies | Relapsed/Refractory B-cell Malignancies | P1 | Not Yet Recruiting | 48 | Open-label | LVIVO-TaVec122 product |
| NCT04094766 Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia | P1 | Withdrawn | — | Open-label | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy |
| NCT03674463 LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | Refractory or Relapsed Multiple Myeloma | P1 | Unknown | 10 | Open-label | LCAR-B4822M CAR-T Cell Immunotherapy |
| NCT03672851 Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia | Acute Leukemia, Acute Leukemia in Relapse | P1 | Terminated | 2 | Open-label | anti-CD123 CAR-T treatment |
| NCT05376345 BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Terminated | 24 | Open-label | LCAR-BCDR cells product |
| NCT05494112 A Sub-Chronic Evaluation of the Safety of Celastrol in Human Subjects | Safety | N/A | Unknown | 35 | Open-label | — |
| NCT05413226 Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility | Safety Issues | N/A | Unknown | 5 | Open-label | — |
| NCT07583030 A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases | Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD) | Early P1 | Not Yet Recruiting | 44 | Open-label | LVIVO-TaVec400 product |
| NCT04027855 A Study on the Collection of Peripheral Blood Mononuclear Cells From Healthy Volunteers for the Development of Allogeneic Cellular Immunotherapy Products | Collection of Peripheral Blood Mononuclear Cells by Means of Apheresis | N/A | Terminated | 4 | Open-label | — |
| NCT04295096 Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product | Healthy Subject | N/A | Unknown | 172 | Open-label | — |
| NCT07399444 A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） | Multiple Myeloma (MM) | Early P1 | Not Yet Recruiting | 38 | Open-label | LVIVO-TaVec400 product |
| NCT06866080 A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases | Relapsed/Refractory Autoimmune Diseases | Early P1 | Withdrawn | — | Open-label | LCAR-AIO T cells |
| NCT06472479 LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | N/A | Not Yet Recruiting | 66 | Open-label | LCAR-M61S cells preparation, LCAR-M61D cells preparation |
| NCT03890198 A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | Gastric Cancer, Pancreatic Ductal Adenocarcinoma | Early P1 | Terminated | 2 | Open-label | LCAR-C182A cells |
| NCT04035226 A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment | Multiple Myeloma | Completed | 254 | — | — |